Currently out of the existing stock ratings of Rahul Sarugaser, 19 are a BUY (73.08%), 6 are a HOLD (23.08%), 1 are a SELL (3.85%).

Rahul Sarugaser

Work Performance Price Targets & Ratings Chart

Analyst Rahul Sarugaser, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 51.79% that have a potential upside of 67.55% achieved within 120 days.

Rahul Sarugaser’s has documented 48 price targets and ratings displayed on 12 stocks. The coverage is on Consumer Defensive, Technology, Healthcare sectors.

Most recent stock forecast was given on QIPT, Quipt Home Medical Corp at 16-May-2024.

Wall Street Analyst Rahul Sarugaser

Analyst best performing recommendations are on DNA (GINKGO BIOWORKS HOLDINGS).
The best stock recommendation documented was for DNA (GINKGO BIOWORKS HOLDINGS) at 10/13/2021. The price target of $580 was fulfilled within 6 days with a profit of $170 (41.46%) receiving and performance score of 69.11.

Average potential price target upside

of $7.75 (158.36%) on FUSN (FUSION PHARMACEUTICALS ).
of $3.47 (43.76%) on PNT (POINT BIOPHARMA GLOBAL).
of $0.9 (26.47%) on QIPT (QUIPT HOME MEDICAL CORP).

SLHG Skylight Health Group VFF Village Farms International AI C3 Ai DNA Ginkgo Bioworks Holdings CRDL Cardiol Therapeutics PROF Profound Medical Corp CRON Cronos Group DBCCF Decibel Cannabis Company MEDXF Medexus Pharmaceuticals FUSN Fusion Pharmaceuticals PNT POINT Biopharma Global QIPT Quipt Home Medical Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Frank Takkinen (LAKE STREET)